Cholinesterase inhibitors in non-Alzheimer dementias

Journal of the American Medical Directors Association

Volumn 4, Issue 6 SUPPL., 2003, Pages

  Gustavson, Andrew R ^a   Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; PLACEBO; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ARTICLE; ATTENTION; BIPOLAR DISORDER; BRAIN INJURY; COGNITION; DELIRIUM; DELUSION; DEMENTIA; DIARRHEA; DISEASE ASSOCIATION; DOWN SYNDROME; DRUG APPROVAL; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; MEMORY CONSOLIDATION; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NAUSEA; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; SCHIZOPHRENIA; TASK PERFORMANCE; UNITED STATES; VERTIGO;

EID: 0348160098     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70409-0     Document Type: Article

References (43)

1. Davis K, Mohs R, Tinklenberg J, et al. Physostigmine: Improvement of long-term memory processes in normal humans. Science 1978;201:272-274.
2. Yesavage JA, Mumenthaler MS, Taylor JL, et al. Donepezil and flight simulator performance: Effects on retention of complex skills. Neurology 2002;59:123-125.
3. Nathan P, Baker A, Carr E, et al. Cholinergic modulation of cognitive function in healthy subjects: Acute effects of donepezil, a cholinesterase inhibitor. Hum Psychopharmacol Clin 2001;16:481-483.
4. Wechler D. WAIS-R Manual. New York: The Psychological Corporation; 1981.
5. Partington JE, Leiter RG. Partington's Pathway Test. The Psychological Service Center Bulletin 1949;1:9-20.
6. Shua-Haim JR, Shua-Haim V, Comsti E. Donepezil in the treatment of age-acquired cognitive deficit. Clin Geriatr Med 2001;9:35-46.
7. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
8. Hemingway-Eltomey JM, Lerner AJ. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. Am J Psychiatry 1999;156:1470.
9. Kishnani PS, Sullivan JA, Walter BK, et al. Cholinergic therapy for Down's syndrome. Lancet 1999;353:1064-1065.
10. Lott IT, Osann K, Doran E, et al. Down syndrome and Alzheimer disease. Arch Neurol 2002;59:1133-1136.
11. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled Study. J Neurol Neurosurg Psychiatry 2002;73:354.
12. Reading P, McKeith I. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord 2001;16:1171-1174.
13. Giladi N, Shabtai S, Benbunan B, et al. The effect of treatment with rivastigmine (Exelon) on cognitive functions of patients with dementia and Parkinson's disease. Neurology 2001;56(suppl):A128.
14. Weber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 2001;108:1319-1325.
15. Fabrini G, Barbanti P, Aurilla C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002;23: 41-43.
16. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002;25:107-110.
17. Bullock RAC. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series. Curr Med Res Opin 2002;18:258-264.
18. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
19. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients. Int Psychogeriatr 1998;10:229-238.
20. Lanctot KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: A case series. Int J Geriatr Psychiatry 2000;15:338-345.
21. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
22. Aarsland D, Kolbjorn B, Karlsen K. Donepezil for dementia with Lewy bodies: A case Study. Int J Geriatr Psychiatry 1999;14:69-74.
23. Kaufer DI, Catt KE, Lopez OL, et al. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998;51:1512.
24. Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 1999;15:280-281.
25. Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001;13:199-205.
26. Cummings JL. Neuropsychiatric Aspects of Alzheimer's Disease and Related Disorders. London: Martin Dunitz; 2002.
27. Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001;57:467-473.
28. Fernandez HH, Friedman JH, Grace J, et al. Donepezil for Huntington's disease. Mov Disord 2000;15:173-176.
29. Griffin S, van Reekum R, Masniac C. A review of cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2003;15:17-26.
30. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002;51:349-357.
31. Pfeiffer E, Jenney E. The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann NY Acad Sci 1957;66:753-764.
32. Rosse R, Deutsch S. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 2002;25:272-275.
33. Stryjer R, Strous R, Bar F, et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 2003;26:12-17.
34. Greene Y, Tariot PN, Wisart H, et al. A 12-week open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000;20:350-356.
35. Wengel SP, Roccaforte WH, Burke JW. Donepezil improves symptoms of delirium in dementia: Implications for future research. J Geriatr Psychiatry Neurol 1998;11:159-161.
36. Burke JR, Roccaforte WH, Wengel SP. Treating visual hallucinations with donepezil. Am J Psychiatry 1999;156:1117-1118.
37. Burt T, Sachs G, Demopulos C. Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 1999;45:959-964.
38. Ringman J, Simmons J. Treatment of REM sleep behavior disorder with donepezil: A report of three cases. Neurology 2000;55:870-871.
39. Perlis M, Smith M, Orff H, et al. The effects of orally administered cholinergic agonist on REM sleep in major depression. Biol Psychiatry 2002;51:457-462.
40. Hoopes SP. Donepezil for Tourette's disorder and ADHD. J Clin Psychopharmacol 1999;19:381-382.
41. Caroff S, Campbell C, Havey J, et al. Treatment of tardive dyskinesia with donepezil: A pilot study. J Clin Psychiatry 2001;62:772-775.
42. Berthier M, Hinojosa J, Martin M, et al. Open-label study of donepezil in chronic post-stroke aphasia. Neurology 2003;60:1218-1219.
43. Nicoldi M, Sicuteri F. Donepezil oral administration acutely relieves long lasting menstrual migraine attacks. Cephalgia 2001;21:493-439.